Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Quality Index
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Quality Index of 1.49x as of September 2025. Operating cash flow of ₩4.51 Billion exceeds net income of ₩3.03 Billion, indicating high earnings quality where cash backs reported profits. Explore 214390 operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kyongbo Pharmaceutical Co Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check cash flow reinvestment rate of Kyongbo Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year earnings quality comparison for Kyongbo Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see Kyongbo Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩149.12 Million | ₩4.64 Billion | ▼ -98.0% |
| 2023 | 1.63x | ₩4.84 Billion | ₩2.97 Billion | ▼ -90.2% |
| 2022 | 16.59x | ₩10.13 Billion | ₩610.59 Million | ▲ +650.0% |
| 2020 | 2.21x | ₩20.80 Billion | ₩9.40 Billion | ▼ -50.6% |
| 2019 | 4.48x | ₩23.67 Billion | ₩5.29 Billion | ▲ +5260.6% |
| 2018 | -0.09x | ₩-1.14 Billion | ₩13.12 Billion | ▼ -106.0% |
| 2017 | 1.44x | ₩25.81 Billion | ₩17.96 Billion | ▼ -27.9% |
| 2016 | 1.99x | ₩25.33 Billion | ₩12.71 Billion | ▲ +1127.5% |
| 2015 | 0.16x | ₩4.24 Billion | ₩26.11 Billion | ▼ -91.3% |
| 2014 | 1.86x | ₩16.04 Billion | ₩8.64 Billion | — |